Pfizer Inc.
TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
Last updated:
Abstract:
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Status:
Application
Type:
Utility
Filling date:
21 Jan 2022
Issue date:
12 May 2022